LXRX Earnings Date: Nov 5, 2026 (Estimated) — Lexicon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is LXRX's next earnings date?
Lexicon Pharmaceuticals, Inc. (LXRX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $4.1M.
How did LXRX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Lexicon Pharmaceuticals, Inc. posted EPS of -$0.07 versus the -$0.05 estimate, a miss of 40.0%. Revenue was $692,000 against a $4.0M estimate. The stock's 1-day post-earnings move was -3.7%.
How much does LXRX stock move after earnings?
LXRX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.7% (up or down) in the day after earnings.
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.05 | -0.07 | -40.00% | $692,000 | ❌ Miss | -3.67% | -4.08% | -7.76% |
| 2026-05-07 | Q1 2026 | -0.04 | 0.00 | +100.00% | $1.1M | ✅ Beat | +5.00% | +52.50% | +19.38% |
| 2026-03-05 | Q4 2025 | -0.07 | -0.04 | +42.86% | $5.5M | ✅ Beat | +0.61% | +5.52% | -2.45% |
| 2025-11-06 | Q3 2025 | -0.07 | -0.04 | +42.86% | $14.2M | ✅ Beat | +3.62% | +11.59% | +1.45% |
| 2025-08-06 | Q2 2025 | -0.08 | 0.01 | +112.50% | $28.9M | ✅ Beat | +9.52% | +0.95% | +1.90% |
| 2025-03-06 | Q4 2024 | -0.12 | -0.09 | +25.00% | $26.6M | ✅ Beat | +6.55% | -2.91% | +13.92% |
| 2024-11-12 | Q3 2024 | -0.16 | -0.18 | -12.50% | $1.8M | ❌ Miss | -8.40% | -25.97% | -30.91% |
| 2024-08-01 | Q2 2024 | -0.19 | -0.17 | +10.53% | $1.6M | ✅ Beat | -16.09% | -16.83% | -14.36% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $475.7M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| License | 99.9% | $475.0M | +1624.5% | $27.5M | $13.2M | $4.3M | $475.0M |
| Product | 0.1% | $680K | -48.6% | $1.3M | $1.0M | $2.3M | $1.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.